Non-specific pan-HDAC inhibitors, which suppress multiple isoforms of HDAC with pleiotropic effects, have anti-inflammatory properties; however, they are also associated with side effects such as fatigue, diarrhea, nausea, and neutropenia [13, 14]. This evidence concerns the gene HDAC9 and neutropenia.